1. Home
  2. AKRO vs AAP Comparison

AKRO vs AAP Comparison

Compare AKRO & AAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • AAP
  • Stock Information
  • Founded
  • AKRO 2017
  • AAP 1929
  • Country
  • AKRO United States
  • AAP United States
  • Employees
  • AKRO N/A
  • AAP N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • AAP Auto & Home Supply Stores
  • Sector
  • AKRO Health Care
  • AAP Consumer Discretionary
  • Exchange
  • AKRO Nasdaq
  • AAP Nasdaq
  • Market Cap
  • AKRO 3.9B
  • AAP 3.9B
  • IPO Year
  • AKRO 2019
  • AAP N/A
  • Fundamental
  • Price
  • AKRO $50.56
  • AAP $58.68
  • Analyst Decision
  • AKRO Strong Buy
  • AAP Hold
  • Analyst Count
  • AKRO 6
  • AAP 19
  • Target Price
  • AKRO $82.50
  • AAP $46.63
  • AVG Volume (30 Days)
  • AKRO 1.1M
  • AAP 3.2M
  • Earning Date
  • AKRO 08-08-2025
  • AAP 08-14-2025
  • Dividend Yield
  • AKRO N/A
  • AAP 1.70%
  • EPS Growth
  • AKRO N/A
  • AAP N/A
  • EPS
  • AKRO N/A
  • AAP N/A
  • Revenue
  • AKRO N/A
  • AAP $8,905,327,000.00
  • Revenue This Year
  • AKRO N/A
  • AAP N/A
  • Revenue Next Year
  • AKRO N/A
  • AAP $1.08
  • P/E Ratio
  • AKRO N/A
  • AAP N/A
  • Revenue Growth
  • AKRO N/A
  • AAP 3.99
  • 52 Week Low
  • AKRO $21.34
  • AAP $28.89
  • 52 Week High
  • AKRO $58.40
  • AAP $70.00
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 44.48
  • AAP 54.33
  • Support Level
  • AKRO $50.60
  • AAP $60.50
  • Resistance Level
  • AKRO $52.55
  • AAP $70.00
  • Average True Range (ATR)
  • AKRO 1.83
  • AAP 3.60
  • MACD
  • AKRO -0.35
  • AAP -0.30
  • Stochastic Oscillator
  • AKRO 17.66
  • AAP 33.18

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About AAP Advance Auto Parts Inc.

Advance Auto Parts is a leading auto-parts retailer in North America with more than 4,000 store and branch locations. About half of the firm's sales are geared toward the professional channel, with the remaining sales in the do-it-yourself market. Through its vast store footprint and distribution network, Advance manages thousands of stock-keeping units for various vehicle makes and models. The retailer primarily competes on the basis of inventory availability and service speed, making the operating efficiency of its hub-and-spoke distribution model critical to meeting customer needs.

Share on Social Networks: